Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations

References

• Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998; 352: 1965–1969
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey M P, Hawkins M M, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977–980
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller L H, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292: 1573–1580
   PubMed Web of Science ®Google Scholar
• Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981–983
   PubMed Web of Science ®Google Scholar
• Smith N L, Heckbert S R, Lemaitre R N, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292: 1581–1587
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe G D, Scarabin P Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 1227–1231
   PubMed Web of Science ®Google Scholar
• Schindler A E, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003; 46(Suppl 1)S7–S16
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004; 47: 277–283
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck A O. Effects of dydrogesterone on the vascular system. Gynecol Endocrinol 2007; 23(Suppl 1)2–8
   PubMedGoogle Scholar
• Oishi A, Ohmichi M, Takahashi K, et al. Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 324: 193–198
   PubMed Web of Science ®Google Scholar
• Simoncini T, Caruso A, Giretti M S, et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006; 86(Suppl 4)1235–1242
   PubMedGoogle Scholar
• Simoncini T, Fu X D, Caruso A, et al. Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. Hum Reprod 2007; 22: 2325–2334
   PubMed Web of Science ®Google Scholar
• Lawson D H, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. Q J Med 1998; 91: 445–452
   Google Scholar
• Garcia Rodriguez L A, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419–425
   PubMed Web of Science ®Google Scholar
• Jick H. A database worth saving. Lancet 1997; 350: 1045–1046
   PubMed Web of Science ®Google Scholar
• Wood L, Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004; 27: 871–881
   Google Scholar
• Jick H, Jick S S, Derby L E. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991; 302: 766–768
   PubMed Web of Science ®Google Scholar
• Jick S S, Kaye J A, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003; 23: 686–689
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Kenemans P, Netelenbos C, et al. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998; 69: 876–882
   PubMed Web of Science ®Google Scholar
• Smolders R G, de Meer K, Kenemans P, Teerlink T, Jakobs C, van der Mooren M J. Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2004; 117: 55–59
   PubMed Web of Science ®Google Scholar
• Chiantera V, Sarti C D, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003; 10: 286–291
   PubMed Web of Science ®Google Scholar
• Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington P N. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. Maturitas 2006; 53: 439–446
   PubMed Web of Science ®Google Scholar
• Bain C A, Walters M R, Lees K R, Lumsden M A. The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women. Hum Reprod 2004; 19: 2411–2414
   PubMed Web of Science ®Google Scholar
• Sare G M, Gray L J, Bath P M. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008; 29: 2031–2041
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J E, Stampfer M J, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008; 168: 861–866
   PubMed Web of Science ®Google Scholar
• Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872–881
   PubMed Web of Science ®Google Scholar
• Suparto I H, Williams J K, Cline J M, Anthony M S, Fox J L. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. Am J Obstet Gynecol 2003; 188: 1132–1140
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–845
   PubMed Web of Science ®Google Scholar